- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02308306
Predictive Markers of the Effects of Opioid Therapy (ABILITY)
Predictive Markers of the Effects of Opioid Therapy in Opioid naïve Patients With Chronic Pain: an International, Multi-centre, Observational Cohort Study (ABILITY)
The overall goal of the ABILITY study is to help improve pain diagnostics and treatment by developing an implementable clinical computerised decision support system based on individual patient characteristics.
The investigators hypothesize that successful pain control with opioids can be predicted before treatment initiation with advanced data analyses of data originating from pre-treatment EEG, QST and pain-related catastrophic thinking.
The primary objective of this study is the identification of markers that can be used to individualize treatment recommendations, i.e. to reliably predict the response of pain to opioids.
Markers are selected among the most promising data and machine-learning methods are used for the prediction. This includes determining the associations between a battery of selected pre-treatment clinical predictive markers and the analgesic effect of opioid treatment in opioid naïve chronic pain patients, including indication and responder identification.
The key secondary objectives are as follows: to investigate pre-treatment clinical predictive markers as predictors of opioid treatment efficacy and effectiveness in terms of the following:
- Pain intensity and unpleasantness
- Use of rescue analgesics
- Physical functioning
- Global improvement and satisfaction with treatment
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Pellenberg
-
Leuven, Pellenberg, Bélgica, 3212
- KU Leuven and the Leuven Centre for Algology & Pain Management
-
-
-
-
-
Aarhus C, Dinamarca, 8000
- Department of Rheumatology, Aarhus University Hospital
-
Give, Dinamarca, 7323
- Friklinikken
-
Ringsted, Dinamarca, 4100
- Hospitalet Valdemar
-
-
-
-
-
Ljubljana, Eslovênia, 1000
- Ljubljana University Medical Centre, Department of Anaesthetics and Surgical Intensive Care
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Pain duration ≥ 3 months.
- Minimum baseline pain intensity ≥ 4 on a 0-10 numerical rating scale (over the past week).
- Maximum baseline pain intensity < 9 on a 0-10 numerical rating scale (over the past week).
- Prescribed opioid treatment (ATC: N02)
- Anticipated to stay on prescribed opioid treatment throughout the study, i.e. >14 days.
- Anticipated to stay on any concomitant non-opioid treatment throughout the study, i.e. >14 days.
- Subject may be male or female, age >18 years old.
- Is willing and able to comply with study procedures as judged by the site investigator.
- Subject has voluntarily signed and dated the study-specific informed consent form, approved by an Independent Ethics Committee, after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent form must be signed before any study-specific procedures are performed.
Exclusion Criteria:
- Has a mental incapacity or language barriers precluding adequate understanding of study procedures.
- Is considered by the site investigator unsuitable to participate in the study for any other reason, for instance due to a significant serious underlying condition.
- Recently received opioids on a daily basis (within the last 10 weeks).
- Current alcohol or substance abuse, according to the site investigator's medical judgement.
- Is anticipated to undergo a painful procedure(s) (e.g. surgery) during the study, which can interfere with the experience of the chronic pain condition for which the subject is to receive opioids.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: Coorte
- Perspectivas de Tempo: Prospectivo
Coortes e Intervenções
Grupo / Coorte |
---|
Opioid analgesics
Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Reduction of chronic pain assessed by 0-10 numerical rating scale (NRS) scores
Prazo: After 14-days of opioid treatment
|
The absolute and percentage change from baseline in ratings of average pain in the past week at Day 14.
Of note, a percentage change of ≥30% is considered clinically significant.
|
After 14-days of opioid treatment
|
Improvement of health-related quality of life assessed by QLQ-C30 scores
Prazo: After 14 days of opioid treatment
|
The absolute and percentage change from baseline in ratings of health-related quality of life in the past week at Day 14.
A subjectively significant change in QLQ-C30 scores is one that is ≥10 from baseline.
|
After 14 days of opioid treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
BPI worst pain in the past week
Prazo: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI least pain in the past week
Prazo: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI current pain in the past week
Prazo: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI pain severity in the past week
Prazo: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI pain interference score
Prazo: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
Improvement score
Prazo: Day 14 post-treatment
|
Proportion with score >4
|
Day 14 post-treatment
|
Concomitant and rescue medication
Prazo: Until 14 days post-treatment
|
Until 14 days post-treatment
|
|
Adverse events
Prazo: Until 14 days post-treatment
|
Number (%) of the following:
|
Until 14 days post-treatment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Asbjørn M Drewes, MD, PhD, DMSci, Aalborg University Hospital, Denmark
- Diretor de estudo: Anne E Olesen, MSc (Pharm), PhD, Aalborg University Hospital, Denmark
- Diretor de estudo: Kasper Grosen, MHSc, PhD, Aarhus University / Aarhus University Hospital, Denmark
- Investigador principal: Mogens Pfeiffer-Jensen, MD, PhD, Aarhus University Hospital, Denmark
- Investigador principal: Michael Kamp-Jensen, MD, PhD, Hospitalet Valdemar, Denmark
- Investigador principal: Bart Morlion, MD, PhD, University of Leuven / University Hospitals Leuven, Belgium
- Investigador principal: Gorazd Pozlep, MD, Ljubljana University Medical Centre, Slovenia
- Investigador principal: Torsten Jonsson, MD, Hospitalet Valdemar, Denmark
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ABILITY
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .